|
|
|
||||||||||
Assistant Professor of Pharmacy Practice, College of Pharmacy, Western University of Health Sciences, Pomona, CA
Pharmacist Clinical Specialist, Perinatal Support Services, Women's Hospital at Long Beach Memorial Medical Center, Long Beach, CA
Clinical Instructor, Department of Obstetrics/Gynecology, University of California at Irvine Medical Center, Irvine, CA
Obstetrician/Gynecologist, Department of Obstetrics/Gynecology, Orange Coast Memorial Medical Center, Fountain Valley, CA
Reprints: Jennifer Le PharmD, College of Pharmacy, Western University of Health Sciences, 309 E. Second St., Pomona, CA 91766-1854, fax 909/469-5539, jle{at}westernu.edu
OBJECTIVE: To provide a comprehensive review of urinary tract infections (UTIs) during pregnancy. All aspects of UTIs, including epidemiology, pathogenesis, resistance, clinical features, diagnosis, treatment, and prevention, were reviewed.
DATA SOURCES: MEDLINE (1966August 2003) and Cochrane Library searches were performed using the key search terms urinary tract infection, pyelonephritis, cystitis, asymptomatic bacteriuria, and resistance.
STUDY SELECTION AND DATA EXTRACTION: All article abstracts were evaluated for relevance. Only articles pertaining to pregnancy were included. The majority of published literature were review articles; the number of original clinical studies was limited.
DATA SYNTHESIS: UTIs are the most common bacterial infections during pregnancy. They are characterized by the presence of significant bacteria anywhere along the urinary tract. Pyelonephritis is the most common severe bacterial infection that can lead to perinatal and maternal complications including premature delivery, infants with low birth weight, fetal mortality, preeclampsia, pregnancy-induced hypertension, anemia, thrombocytopenia, and transient renal insufficiency. Enterobacteriaceae account for 90% of UTIs. The common antibiotics used are nitrofurantoin, cefazolin, cephalexin, ceftriaxone, and gentamicin.
CONCLUSIONS: Therapeutic management of UTIs in pregnancy requires proper diagnostic workup and thorough understanding of antimicrobial agents to optimize maternal outcome, ensure safety to the fetus, and prevent complications that lead to significant morbidity and mortality in both the fetus and the mother.
Key Words: bacteriuria, cystitis, gestation, pregnancy, pyelonephritis, urinary tract infection
Published Online, August 31, 2004. www.theannals.com, DOI 10.1345/aph.1D630
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-04-030-H01
This article has been cited by other articles:
![]() |
M. L Feldkamp, J. Reefhuis, J. Kucik, S. Krikov, A. Wilson, C. A Moore, J. C Carey, and L. D Botto Case-control study of self reported genitourinary infections and risk of gastroschisis: findings from the national birth defects prevention study, 1997-2003 BMJ, June 21, 2008; 336(7658): 1420 - 1423. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lee, P. Bozzo, A. Einarson, and G. Koren Urinary tract infections in pregnancy Can Fam Physician, June 1, 2008; 54(6): 853 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhang, H. Wang, J. D. Unadkat, and Q. Mao Breast Cancer Resistance Protein 1 Limits Fetal Distribution of Nitrofurantoin in the Pregnant Mouse Drug Metab. Dispos., December 1, 2007; 35(12): 2154 - 2158. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Cimolai and T. Cimolai Nitrofurantoin and pregnancy Can. Med. Assoc. J., June 19, 2007; 176(13): 1860 - 1861. [Full Text] [PDF] |
||||
![]() |
K. Wroblewska-Seniuk, R. Selvarangan, A. Hart, R. Pladzyk, P. Goluszko, A. Jafari, L. du Merle, S. Nowicki, C. Yallampalli, C. Le Bouguenec, et al. Dra/AfaE Adhesin of Uropathogenic Dr/Afa+ Escherichia coli Mediates Mortality in Pregnant Rats Infect. Immun., November 1, 2005; 73(11): 7597 - 7601. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C Arya and N. Agarwal Comment: urinary tract infections during pregnancy Ann. Pharmacother., May 1, 2005; 39(5): 977 - 977. [Full Text] |
||||